Opin vísindi

Prenatal exposure to antiseizure medications and fetal growth : a population-based cohort study from the Nordic countries

Show simple item record

dc.contributor.author Christensen, Jakob
dc.contributor.author Zoega, Helga
dc.contributor.author Leinonen, Maarit K.
dc.contributor.author Gilhus, Nils Erik
dc.contributor.author Gissler, Mika
dc.contributor.author Igland, Jannicke
dc.contributor.author Sun, Yuelian
dc.contributor.author Tomson, Torbjörn
dc.contributor.author Alvestad, Silje
dc.contributor.author Bjørk, Marte Helene
dc.contributor.author Dreier, Julie Werenberg
dc.date.accessioned 2024-04-13T01:06:14Z
dc.date.available 2024-04-13T01:06:14Z
dc.date.issued 2024-03
dc.identifier.citation Christensen , J , Zoega , H , Leinonen , M K , Gilhus , N E , Gissler , M , Igland , J , Sun , Y , Tomson , T , Alvestad , S , Bjørk , M H & Dreier , J W 2024 , ' Prenatal exposure to antiseizure medications and fetal growth : a population-based cohort study from the Nordic countries ' , The Lancet Regional Health - Europe , vol. 38 , 100849 . https://doi.org/10.1016/j.lanepe.2024.100849
dc.identifier.issn 2666-7762
dc.identifier.other 219058090
dc.identifier.other 5219d32b-f398-4a7a-92c8-508424956a49
dc.identifier.other 85186609776
dc.identifier.uri https://hdl.handle.net/20.500.11815/4817
dc.description Publisher Copyright: © 2024 The Author(s)
dc.description.abstract Background: The short- and long-term consequences of restricted fetal growth cause considerable concern, and how prenatal exposure to different antiseizure medications (ASMs) affects fetal growth remains uncertain. Methods: This was a population-based cohort study of liveborn singleton children born in Denmark, Finland, Iceland, Norway, and Sweden from 1996 to 2017. Prenatal exposure was defined as maternal filling of prescriptions for ASM during pregnancy registered in national prescription registries and primary outcomes were adjusted odds ratios (aORs) of microcephaly or being born small for gestational age. Findings: We identified 4,494,918 children (males: 51.3%, 2,306,991/4,494,918), including 38,714 (0.9%) children of mothers with epilepsy. In the overall population, prenatal monotherapy exposure with carbamazepine (aOR: 1.25 (95% CI: 1.12–1.40)), pregabalin (aOR: 1.16 (95% CI: 1.02–1.31)), oxcarbazepine (aOR: 1.48 (95% CI: 1.28–1.71)), clonazepam (aOR: 1.27 (95% CI: 1.10–1.48)), and topiramate (aOR: 1.48 (95% CI: 1.18–1.85)) was associated with risk of being born small for gestational age, and carbamazepine was associated with microcephaly (aOR: 1.43 (95% CI: 1.17–1.75)). In children of mothers with epilepsy, prenatal exposure to carbamazepine (aOR: 1.27 (95% CI: 1.11–1.47)), oxcarbazepine (aOR: 1.42 (95% CI: 1.18–1.70)), clonazepam (aOR: 1.40 (95% CI: 1.03–1.89)), and topiramate (aOR: 1.86 (95% CI: 1.36–2.54)) was associated with being born small for gestational age; carbamazepine, with microcephaly (aOR: 1.51 (95% CI: 1.17–1.95)). No associations with small for gestational age and microcephaly were identified after prenatal exposure to lamotrigine, valproate, gabapentin, levetiracetam, phenobarbital, acetazolamide, phenytoin, clobazam, primidone, zonisamide, vigabatrin, ethosuximide and lacosamide, but except for lamotrigine, valproate, gabapentin, and levetiracetam, numbers of exposed children were small. Interpretation: Prenatal exposure to carbamazepine, oxcarbazepine, clonazepam, and topiramate was associated with increased risk of being born small for gestational age in both the overall population and in children of women with epilepsy suggesting that prenatal exposure to these drugs is associated with fetal growth restriction. Funding: The NordForsk Nordic Program on Health and Welfare (83539), the Independent Research Fund Denmark (1133-00026B), the Danish Epilepsy Association, the Central Denmark Region, the Novo Nordisk Foundation (NNF16OC0019126 and NNF22OC0075033), and the Lundbeck Foundation (R400-2022-1205).
dc.format.extent 622196
dc.format.extent
dc.language.iso en
dc.relation.ispartofseries The Lancet Regional Health - Europe; 38()
dc.rights info:eu-repo/semantics/openAccess
dc.subject Antiepileptic drugs
dc.subject Birth weight
dc.subject Gestational age
dc.subject Head circumference
dc.subject In utero
dc.subject Pregnancy
dc.subject Small for gestational age
dc.subject Internal Medicine
dc.subject Oncology
dc.subject Health Policy
dc.title Prenatal exposure to antiseizure medications and fetal growth : a population-based cohort study from the Nordic countries
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.1016/j.lanepe.2024.100849
dc.relation.url http://www.scopus.com/inward/record.url?scp=85186609776&partnerID=8YFLogxK
dc.contributor.department Faculty of Medicine


Files in this item

This item appears in the following Collection(s)

Show simple item record